2026 will bring more GLP-1 weight loss pills
Novo Nordisk and Eli Lilly are expected to bring GLP-1 pills to market in the new year, which is expected to boost the number being treated.
TL;DR
- Manufacturing, insurance, and needle-phobia barriers for GLP-1 obesity drugs are decreasing.
- Oral GLP-1 medications are expected to launch, improving convenience and potentially lowering costs.
- A significant portion of consumer spending, particularly food and beverage, is projected to come from GLP-1 households by 2030.
- GLP-1 drug users are changing consumption habits, prioritizing protein, portion control, and fiber, and reducing alcohol intake.
- These shifts create opportunities for restaurants offering healthier, smaller-portioned meals and for packaged food companies focusing on fresh or refrigerated options.
- The GLP-1 market is expanding beyond diabetes and obesity, with companies investigating other potential indications.